Property | Value |
?:abstract
|
-
There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.
|
?:creator
|
|
?:doi
|
|
?:doi
|
-
10.1007/s13365-020-00884-7
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/d0a66453a29c0151a7569e4ded8bd9703cbc75b9.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7384559.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease
|
?:type
|
|
?:year
|
|